Efficacy, Pharmacokinetics, Biodistribution and Excretion of a Novel Acylated Long-Acting Insulin Analogue INS061 in Rats

References

• International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels,Belgium: 2019. Available from: https://www.diabetesatlas.org.
   Google Scholar
• ChamberlainJJ, JohnsonEL, LealS, et al. Cardiovascular disease and risk management: review of the American diabetes association standards of medical care in diabetes. Ann Intern Med. 2018;168:640–651. doi:10.7326/M18-022229610837
   PubMed Web of Science ®Google Scholar
• FongDS, AielloL, GardnerTW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27S1:S84–87. doi:10.2337/diacare.27.2007.S84
   Google Scholar
• WolfG, RitzE. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol. 2003;14:1396–1405. doi:10.1097/01.ASN.0000065639.19190.CF12707409
   PubMed Web of Science ®Google Scholar
• KobayashiM, ZochodneDW. Diabetic neuropathy and the sensory neuron: new aspects of pathogenesis and their treatment implications. J Diabetes Inv. 2018;9:1239–1254. doi:10.1111/jdi.12833
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2018. Diabetes Care. 2018;41S1:S105–S118. doi:10.2337/dc18-S010
   Web of Science ®Google Scholar
• WangY, XingL, YuH, et al. Prevalence of dental caries in children and adolescents with type 1 diabetes: a systematic review and meta-analysis. BMC Oral Health. 2019;19:213. doi:10.1186/s12903-019-0903-531521152
   PubMed Web of Science ®Google Scholar
• ZorenaK, RaczyńskaD, RaczyńskaK. Biomarkers in diabetic retinopathy and the therapeutic implications. Mediat Inflam. 2013;193604. doi:10.1155/2013/193604
   Web of Science ®Google Scholar
• JacobsonAM, BraffettBH, ClearyPA, et al. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life. Diabetes Care. 2013;36:3131–3138. doi:10.2337/dc12-210923835693
   PubMed Web of Science ®Google Scholar
• TrentoM, PasseraP, TrevisanM, et al. Quality of life, impaired vision and social role in people with diabetes: a multicenter observational study. Acta Diabetol. 2013;50:873–877. doi:10.1007/s00592-013-0470-123526056
   PubMed Web of Science ®Google Scholar
• DowarahJ, SinghVP. Anti-diabetic drugs recent approaches and advancements. Bioorg Med Chem. 2020;28:115263. doi:10.1016/j.bmc.2019.11526332008883
   PubMed Web of Science ®Google Scholar
• CharbonnelB, ArodaVR, WesterbackaJ, et al. 131-LB: differences in HbA1c reduction between insulin Glargine 300 U/mL (Gla-300) and insulin Degludec 100 U/mL (IDeg-100) in adults ≥70 years of age with T2DM in the BRIGHT trial. Diabetes. 2019;68:131–LB. doi:10.2337/db19-131-LB30305366
   PubMed Web of Science ®Google Scholar
• DuttaroyA, KanakarajP, OsbornBL, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes. 2005;54:251–258. doi:10.2337/diabetes.54.1.25115616036
   PubMed Web of Science ®Google Scholar
• BednarekE, SitkowskiJ, BocianW, et al. Structure and pharmaceutical formulation development of a new long-acting recombinant human insulin analog studied by NMR and MS. J Pharmaceut Biomed. 2016;135:126–132. doi:10.1016/j.jpba.2016.12.005
   Web of Science ®Google Scholar
• DardanoA, BianchiC, PratoSD, et al. Insulin Degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag. 2014;10:465–475.25143741
   PubMedGoogle Scholar
• MayerJP, ZhangF, DimarchiRD. Insulin structure and function. Biopolymers. 2007;88(5):687–713. doi:10.1002/bip.2073417410596
   PubMed Web of Science ®Google Scholar
• SliekerLJ, BrookeGS, DimarchiRD, et al. Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia. 1997;40(2):S54–S61. doi:10.1007/s0012500514029248702
   PubMed Web of Science ®Google Scholar
• Sun PY, Zhang LS, Liu JJ, et al. Human insulin analogue and acylated derivative thereof. European Patent EP2784085A1. 2014.
   Google Scholar
• TeschGH, AllenTJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrol. 2007;12:261–266. doi:10.1111/j.1440-1797.2007.00796.x
   PubMed Web of Science ®Google Scholar
• LvJ, PanY, LiX, et al. The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide. PLoS One. 2014;9:e96833. doi:10.1371/journal.pone.009683324805918
   PubMed Web of Science ®Google Scholar
• KimudaSG, BiraroIA, BagayaBS, et al. Characterising antibody avidity in individuals of varied Mycobacterium tuberculosis infection status using surface plasmon resonance. PLoS One. 2018;13:e0205102. doi:10.1371/journal.pone.020510230312318
   PubMed Web of Science ®Google Scholar
• SteinickeF, Oltmann-NordenI, WätzigH. Long term kinetic measurements revealing precision and general performance of surface plasmon resonance biosensors. Anal Biochem. 2017;530:94–103. doi:10.1016/j.ab.2017.05.00928501475
   PubMed Web of Science ®Google Scholar
• KornM, WohlfartP, GossasT, et al. Comparison of metabolic and mitogenic response in vitro of the rapid-acting insulin lispro product SAR342434, and US- and EU-approved Humalog®. Regul Toxicol Pharm. 2019;109:104497. doi:10.1016/j.yrtph.2019.104497
   Web of Science ®Google Scholar
• KerlanV, GouetD, MarreM, et al. Use of insulin Degludec, a new basal insulin with an ultra-long duration of action, in basal–bolus therapy in type 1 and type 2 diabetes. Ann Dendocrinol. 2013;74:487–490. doi:10.1016/j.ando.2013.04.004
   Web of Science ®Google Scholar
• StandlE, OwenDR. New long-acting basal insulins: does benefit outweigh cost. Diabetes Care. 2016;39(S2):S172–S179. doi:10.2337/dcS15-301127440830
   PubMed Web of Science ®Google Scholar
• RiddleMC. Lessons from Peglispro: imagine how to improve drug development and affordability. Diabetes Care. 2016;39(4):499–501. doi:10.2337/dc15-275427208365
   PubMed Web of Science ®Google Scholar
• MeytsPD. Insulin and its receptor: structure, function and evolution. Bioessays. 2004;26:1351–1362. doi:10.1002/bies.2015115551269
   PubMed Web of Science ®Google Scholar
• GammeltoftS. Insulin receptors: binding kinetics and structure-function relationship of insulin. Physiol Rev. 1984;64(4):1321–1378. doi:10.1152/physrev.1984.64.4.13216387730
   PubMed Web of Science ®Google Scholar
• SinclairAJ, SignoreA, BomanjiJ, et al. In vivo kinetics of 123I-labelled insulin: studies in normal subjects and patients with diabetes mellitus. Nucl Med Comm. 1987;8:779–786. doi:10.1097/00006231-198710000-00003
   Web of Science ®Google Scholar
• IozzoP, OsmanS, GlaserM, et al. In vivo imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodine-124 labelled human insulin. Nucl Med Biol. 2002;29:73–82. doi:10.1016/S0969-8051(01)00286-411786278
   PubMed Web of Science ®Google Scholar
• LiuY, WangHY, ZhouL, et al. Biodistribution, activation, and retention of proinsulin-transferrin fusion protein in the liver: mechanism of liver-targeting as an insulin prodrug. J Control Release. 2018;275:189–191. doi:10.1016/j.jconrel.2018.02.030
   Web of Science ®Google Scholar
• SommermanEF, PritchardPH, CullisPR. 125I labelled inulin: a convenient marker for deposition of liposomal contents. Biochem Biophys Res. 1984;122:319–324. doi:10.1016/0006-291X(84)90477-7
   PubMed Web of Science ®Google Scholar
• HongG, Bazin-RedureauMI, ScherrmannJMG. Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. J Pharm Sci. 1999;88:147–153. doi:10.1021/js970335n9874717
   PubMed Web of Science ®Google Scholar
• WronkowitzN, HartmannT, GörgensSW, et al. LAPS Insulin115: a novel ultra-long-acting basal insulin with a unique action profile. Diabetes Obes Metab. 2017;19(12):1722–1731. doi:10.1111/dom.1300628497570
   PubMed Web of Science ®Google Scholar
• ZhaiJ, LiL, DongL, et al. Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography–tandem mass spectrometry method and its application. Biomed Chromatogr. 2020;34(10):e4921. doi:10.1002/bmc.492132537846
   PubMed Web of Science ®Google Scholar
• LiYH, MengQ, YangMB, et al. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B. 2019;9:1113–1144.31867160
   PubMed Web of Science ®Google Scholar
• BanksWA, MorleyJE, LynchJL, et al. Insulin detemir is not transported across the blood-brain barrier. Peptides. 2010;31:2284–2288. doi:10.1016/j.peptides.2010.09.01120868713
   PubMed Web of Science ®Google Scholar
• RabkinR, RyanMP, DuckworthWC. The renal metabolism of insulin. Diabetologia. 1984;27(3):351–357. doi:10.1007/BF003048496389240
   PubMed Web of Science ®Google Scholar
• DuckworthWC, BennettRG, HamelFG. Insulin degradation: progress and potential. Endocr Rev. 1998;5:608–624.
   Google Scholar
• PiccininiF, BergmanRN. The Measurement of Insulin Clearance. Diabetes Care. 2020;43(9):2296–2302. doi:10.2337/dc20-075032910777
   PubMed Web of Science ®Google Scholar
• TambasciaMA, EliaschewitzFG. Degludec: the new ultra-long insulin analogue. Diabetol Metab Syndr. 2015;7(1):57. doi:10.1186/s13098-015-0037-026136850
   PubMed Web of Science ®Google Scholar